Antares Pharma — Investor Presentation (January 2017)
25 slides from Antares Pharma's investor presentation, Jan 27, 2017
Slide 1: Investor Presentation January 2017
NASDAQ: ATRS Investor Presentation January 2017 EX 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ mate
Slide 3: Antares Pharma: Specialty Pharmaceutical Company
Antares Pharma A Growing, Revenue Generating State-of-the-Art Specialty Pharmaceutical Company An Innovative Leader In Self-Administered Injection Technology Two combination products approved and on the market (OTREXUP®, Sumatriptan) Three ANDA drug device combination products under review with firs
Slide 4: Diverse Pipeline of Proprietary and Partnered Products
Diverse Pipeline of Proprietary and Partnered Products Product Overview Product Brand/Partner Device Drug Indications Development/ Approval Status Financial Consideration OTREXUP™ Vibex Methotrexate (MTX) RA; pJIA Psoriasis US launch 2014 Proprietary Product Sales Launched with in-house sales force
Slide 5: 2016 Accomplishments
2016 Accomplishments QuickShot® Testosterone NDA submitted December 21, 2016 Sumatriptan mid-year launch by Teva Growth of OTREXUP® +11% Through the first 9 months of 2016 Alliance Business progress: Makena® life cycle management collaboration with AMAG – PK study ongoing, AMAG expects sNDA submissi
Slide 6: NDA Filing For QuickShot Testosterone
NDA Filing For QuickShot® Testosterone NDA submitted December 21, 2016 Possible launch in late 2017 / early 2018 Final safety and pain data from 26 and 52 week studies reported QuickShot® Testosterone
Slide 7: STEADY Summary – QST-13-003
STEADY Summary – QST-13-003 7 The majority of patients achieved mean TT Cavg168h within the defined range at Week 12 TT concentrations <300 ng/dL were observed in less than 3% in any SCTE-AI dose group Overall patient satisfaction with injections, sexual function and mood improved from baseline and
Slide 8: QST-13-003 - Mean Testosterone Ctrough Over Weeks
QST-13-003 - Mean Testosterone Ctrough Over 52 Weeks 6 12 18 26 38 52 Week 1, pre-dose
Slide 9: Patient Compliance and Satisfaction
Median treatment compliance was 100% 1,510 of 1,519 (99.4%) of observed injections in the 52 week study were reported as painless Satisfaction with self-injections, ease-of-use, self-image, and injection site reactions increased from Baseline to Week 12 Overall improvement was observed across all Ps
Slide 10: Testosterone Therapy Innovation QST
Testosterone Therapy Innovation QST
Slide 11: Testosterone Replacement Market: 2015-16 Retail Prescriptions
Testosterone Replacement Market: 2015-16 Retail Prescriptions 11 Symphony Health Solutions: Phast IDV 2016 2015
Slide 12: Sumatriptan Injection USP Launch
Sumatriptan Injection USP Launch 4mg & 6mg doses commercially available 7/1/16 Q316 revenue of $3.4 million generated from the shipment of finished product to Teva - $6.3 million shipped year-to-date 50/50 profit split with Teva Antares produces final packaged product & sells to Teva at cost Teva di
Slide 13: OTREXUP
OTREXUP® First approved methotrexate for subcutaneous injection in the U.S. Single-use, disposable & easy to use Collar activated, no push button, easy to grip and virtually painless Needle guard prevents accidental sticks Audible click followed by red indicator to confirm injection is complete Appr
Slide 14: OTREXUP Growth
OTREXUP® Growth Q316 Revenues of $3.9 million +9% vs. Q315, and nine month year-to-date 2016 revenue of $11 million +11% vs. same period last year Committed to growing OTREXUP®: Making it easier for patients and physicians to get Otrexup Modifying certain sales and marketing tactics to focus on prod
Slide 15: Near Term Alliance Business Opportunities
Near Term Alliance Business Opportunities Epinephrine Exenatide Makena 15 Teriparatide
Slide 16: VIBEX Epinephrine
VIBEX® Epinephrine Teva filed ANDA amendment with FDA in December 2014, Complete Response Letter (CRL) issued February 2016, Teva and Antares working together to answer FDA questions Shipped $1.1 million in devices to Teva in Q316 and ~$18 million to date Agreement with Teva – ATRS will receive marg
Slide 17: Generic Byetta (exenatide) Multi-Dose Pen
Generic Byetta® (exenatide) Multi-Dose Pen Teva announced settlement with AstraZeneca and Amylin which allows Teva to launch on October 15, 2017, pending FDA approval Teva filed ANDA in December 2014 and it is under review – Antares believes Teva has first to file status and 180 day marketing exclus
Slide 18: Generic Forteo (teriparatide) Multi-Dose Pen
Generic Forteo® (teriparatide) Multi-Dose Pen Teva ANDA accepted by FDA 2/16; Lilly filed a lawsuit in response to Teva’s Paragraph IV notice, 30 month stay expires in August 2018. Lilly has agreed not to sue Teva on the device patent (which expires in 2025) - last to expire patent is now August 201
Slide 19: Makena - Continued Progress Toward Q217 sNDA Filing
Makena® - Continued Progress Toward Q217 sNDA Filing AMAG/Makena® alliance began in 2014 Antares is using the QuickShot device to develop a once-weekly subcutaneous injection of Makena Potentially better patient compliance Potentially easier administration Currently administered IM with a large-gaug
Slide 20: Device Technology Platforms Allow For Multiple Product Development
Device Technology Platforms Allow For Multiple Product Development and Business Alliance Opportunities
Slide 21: Third Quarter 2016 Revenue Mix
Third Quarter 2016 Revenue Mix Three Months Ended Sep 30 Increase 2016 2015 (Decrease) OTREXUP $ 3,904 $ 3,593 9% Auto injector and pen injector devices 5,944 3,240 83% Needle-free injector devices & components 1,202 1,194 1% Total Product Sales 11,050 8,027 38% Development revenue 2,101 2,608 -19%
Slide 22: Third Quarter 2016 Financial Results
Third Quarter 2016 Financial Results Three Months Ended Sep 30 Increase 2016 2015 (Decrease) Total Revenue $ 13,479 $ 11,086 22% Cost of Revenue 8,034 5,100 58% Gross Profit 5,445 5,986 -9% % Revenues 40% 54% Research & Development 5,958 5,142 16% Selling, General & Administrative 5,623 6,611 -15% T
Slide 23: Year-to-Date 2016 Financial Results
Year-to-Date 2016 Financial Results Nine Months Ended Sep 30 Increase 2016 2015 (Decrease) Total Revenue $ 38,026 $ 33,854 12% Cost of Revenue 22,128 13,482 64% Gross Profit 15,898 20,372 -22% % Revenues 42% 60% Research & Development 15,555 14,089 10% Selling, General & Administrative 20,241 20,254
Slide 24: Investment Considerations
Investment Considerations A growing, revenue generating company – $13.5 million in Q316 and $38.0 million through the nine month period ended 9/30/16 2016 Accomplishments: QST NDA submission to FDA December 21st Sumatriptan Injection USP launched – TRx share after 6 months - ~22% Growth of OTREXUP™
Slide 25: NASDAQ: ATRS Investor Presentation January 2017
NASDAQ: ATRS Investor Presentation January 2017
Antares Pharma — Investor Presentation (January 2017) on 6ix